Recently, Global Authorid has released the list of the “World’s Top 100,000 Scientists” which is based on all-round measurement of scores from Metrics, cited times of papers, types of papers, the author’s contribution to papers, the author’s H index and other indicators to ,make precise assessment of scholars’ academic influence. Altogether, 11,642 Chinese scholars are named on this list. Notably, prof. Wu Yilong, a leading figure in clinical study on lung cancer working in Guangdong Provincial People’s Hospital, is among the top ten scientists from mainland China in the field of clinical medicine.

The Top Ten List of the World’s Top 100,000 Scientists in Clinical Medicine

Professor Wu Yilong, an internationally influential and major researcher on multidisciplinary clinical trials of lung cancer, is committed to the clinical and translational study of this disease. So far, as a major researcher in this field both at home and abroad, he has led 16 international clinical trials and 110 domestic multicenter clinical trials, some of which are included in 27 lung cancer guidelines  of 15 countries and regions, including America, Europe, and Japan. His academic achievements have set a new standard for the treatment for lung cancer in the world and transformed the landscape of how to treat it. Joining the top ten of the list demonstrates his profound academic attainments. Also, being a leading figure, he has promoted Chinese clinical study on lung cancer to go global, remarkably improving China’s status in terms of lung cancer clinical study among international oncology academia.

Prof. Wu Yilong, the First Chinese Scholar as the President of World Conference on Lung Cancer

He has devoted himself to studying precision treatment for lung cancer for many years, introducing the technology of lung cancer molecular typing. More than 18 lung cancer medicines which are produced based on his study have gained marketing approval, bringing benefits for patients with this disease. In 2015, he was awarded the IASLC Scientific Award. In 2020, he, as the WCLC conference president, showcased China’s academic accomplishments in this field. In addition, his papers have been published on top medical journals such as N Engl J Med, Lancet series, and J Clin Oncol, enabling him to be one of the Highly Cited Chinese Researchers for consecutive years.

Prof. Wu Yilong on the List of Elsevier 2020 “Highly Cited Chinese Researchers”

Being the chief expert in treatment for single disease of lung cancer, he has also trained a large number of exceptional, young and middle-aged talents. Specifically, he has established a team in Guangdong Lung Cancer Institute and guided the team to keep improving their treatment and research level so as to resolve difficulties in this field. He aims to provide the highest quality of medical services for lung cancer patients and make Guangdong Provincial People’s Hospital more prominent in terms of oncology treatment and research.

The team of Guangdong Lung Cancer Institute

Zheng Meimei and Gan Bin